Literature DB >> 32061467

Prediction of Platinum-based Chemotherapy Response in Advanced High-grade Serous Ovarian Cancer: ADC Histogram Analysis of Primary Tumors.

Jing Lu1, Hai Ming Li2, Song Qi Cai3, Shu Hui Zhao4, Feng Hua Ma5, Yong Ai Li1, Xiao Liang Ma1, Jin Wei Qiang6.   

Abstract

RATIONALE AND
OBJECTIVES: To investigate the feasibility of apparent diffusion coefficient (ADC) histogram analysis of primary advanced high-grade serous ovarian cancer (HGSOC) to predict patient response to platinum-based chemotherapy.
MATERIALS AND METHODS: A total of 70 patients with 102 advanced stage HGSOCs (International Federation of Gynecology and Obstetrics (FIGO) stages III-IV) who received standard treatment of primary debulking surgery followed by the first line of platinum-based chemotherapy were retrospectively enrolled. Patients were grouped as platinum-resistant and platinum-sensitive according to whether relapse occurred within 6 months. Clinical characteristics, including age, pretherapy CA125 level, International Federation of Gynecology and Obstetrics stage, residual tumor, and histogram parameters derived from whole tumor and solid component such as ADCmean; 10th, 20th, 25th, 30th, 40th, 50th, 60th, 70th, 75th, 80th, 90th percentiles; skewness and kurtosis, were compared between platinum-resistant and platinum-sensitive groups.
RESULTS: No significantly different clinical characteristics were observed between platinum-sensitive and platinum-resistant patients. There were no significant differences in any whole-tumor histogram-derived parameters between the two groups. Significantly higher ADCmean and percentiles and significantly lower skewness and kurtosis from the solid-component histogram parameters were observed in the platinum-sensitive group when compared with the platinum-resistant group. ADCmean, skewness and kurtosis showed moderate prediction performances, with areas under the curve of 0.667, 0.733 and 0.616, respectively. Skewness was an independent risk factor for platinum resistance.
CONCLUSION: Pretreatment ADC histogram analysis of primary tumors has the potential to allow prediction of response to platinum-based chemotherapy in patients with advanced HGSOC.
Copyright © 2020 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apparent diffusion coefficient; Chemotherapy; High-grade serous ovarian cancer; Histogram analysis; Magnetic resonance imaging

Mesh:

Substances:

Year:  2020        PMID: 32061467     DOI: 10.1016/j.acra.2020.01.024

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  5 in total

1.  Apparent diffusion coefficient histogram analysis for differentiating solid ovarian tumors.

Authors:  Renwei Liu; Ruifeng Li; Jinzhi Fang; Kan Deng; Cuimei Chen; Jianhua Li; Zhiqing Wu; Xiaoxu Zeng
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

2.  Whole lesion histogram analysis of apparent diffusion coefficient predicts therapy response in locally advanced rectal cancer.

Authors:  Mayra Evelia Jiménez de Los Santos; Juan Armando Reyes-Pérez; Victor Domínguez Osorio; Yolanda Villaseñor-Navarro; Liliana Moreno-Astudillo; Itzel Vela-Sarmiento; Isabel Sollozo-Dupont
Journal:  World J Gastroenterol       Date:  2022-06-21       Impact factor: 5.374

3.  Muscle-invasive bladder cancer: pretreatment prediction of response to neoadjuvant chemotherapy with diffusion-weighted MR imaging.

Authors:  Xinxin Zhang; Yichen Wang; Jin Zhang; Xiaojuan Xu; Lianyu Zhang; Miaomiao Zhang; Lizhi Xie; Jianzhong Shou; Yan Chen
Journal:  Abdom Radiol (NY)       Date:  2022-03-20

4.  Development of a MRI-Based Radiomics Nomogram for Prediction of Response of Patients With Muscle-Invasive Bladder Cancer to Neoadjuvant Chemotherapy.

Authors:  Xinxin Zhang; Yichen Wang; Jin Zhang; Lianyu Zhang; Sicong Wang; Yan Chen
Journal:  Front Oncol       Date:  2022-05-11       Impact factor: 5.738

5.  Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma.

Authors:  Masakazu Sato; Sho Sato; Daisuke Shintani; Mieko Hanaoka; Aiko Ogasawara; Maiko Miwa; Akira Yabuno; Akira Kurosaki; Hiroyuki Yoshida; Keiichi Fujiwara; Kosei Hasegawa
Journal:  BMC Cancer       Date:  2022-01-13       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.